Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study - Wikidata - wikimedia - TriplyDB

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

http://www.wikidata.org/entity/Q28202824

about

sameAs

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer Bispecific digoxigenin-binding antibodies for targeted payload delivery World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Recent trends in targeted anticancer prodrug and conjugate design.Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.Antibody-DM1 conjugates as cancer therapeutics.Antibody Drug Conjugates: Nonclinical Safety Considerations.Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.Antibody-cytotoxic agent conjugates for cancer therapy.Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer.Anticancer carrier-linked prodrugs in clinical trials.CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Pharmacokinetic considerations for antibody drug conjugates.Optimising the delivery of tubulin targeting agents through antibody conjugation.ADME of antibody-maytansinoid conjugates Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.In vivo biotransformations of antibody-drug conjugates.Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.Protein based therapeutic delivery agents: Contemporary developments and challenges.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study.Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.Immunogenicity screening in protein drug development.

P2860

Q24624489-4462CC1A-1AD1-4C56-84DD-ADC94DCD788C Q26780335-9E6340B2-60CC-422E-803B-26654B6DF513 Q26830923-C5519E92-2C98-4B39-B3C7-D5ADAD211981 Q26853171-9C22CEF0-5F49-4B5C-86A1-B0B61FCDB01B Q27667652-74651622-F2F0-4A22-B5BF-67323CD903CB Q30414399-01F0A126-0FA1-40AD-8408-309A39E4F485 Q30524836-2BECC8C6-A265-4D1F-B3D9-601A6630B0E3 Q33311571-E426B6E0-3F1E-4094-919B-FD6D020237A7 Q33402778-A9D1E741-2004-4A54-A62B-FFDBAACAD55C Q33409083-0F58A282-CC6F-4B87-B247-385FEF170E25 Q33573762-52BF1491-D1AF-4462-AEFD-92AEA2043F82 Q34162875-8B43D259-151B-4692-B388-B4F7807806FE Q34177359-A6928ED3-3E23-4FD6-AEBC-3B0CA9AC4E65 Q35967917-4D3CF09F-7B54-48AB-80D8-81362BD095CC Q36200153-CE198F40-CA19-49E7-BB18-EF2D6EEBBA56 Q36316831-8078DC42-D4BE-4DB4-8E25-AD02D7FDA559 Q36366709-3D1D2394-4083-4B6E-8A8C-F488C7B37062 Q36378949-05B0BA0D-A9E8-4AB0-9BCF-39034F6A1427 Q36407249-3D0E519D-CF39-47A5-8FF8-2F9F999756E6 Q36861603-FBAF8DAF-7681-4FC7-8F4A-D31DD8119E1E Q37402888-5366C05E-78E1-42A3-93D0-79A4C3CFB7B3 Q37854644-9F0812B6-CE73-4D6A-BA21-D638E1224EF3 Q38022192-D6080A69-E573-4B7B-8AC3-883BBEEC3852 Q38024991-8CD3B802-23A0-42EE-9012-4BC31DB2E211 Q38033114-C9CA8791-7C96-41B0-9236-8D9B7C76E07E Q38065955-B65E09D9-BB2F-4B74-A7F8-089A1F1C1B38 Q38262066-1537D58E-085E-4DAE-B4A4-C38BBD3222D7 Q38489049-CDB42B30-0818-489D-921D-01EF1CEA3B41 Q38557525-8007D909-25ED-4878-BFA1-AC59EC14C736 Q38798481-929D5BE0-BCF7-4A7E-B8B6-A08C77D6E299 Q38817525-1C1C82BA-E831-4038-86DF-F30AFA36A839 Q39273739-2230A0B2-64A0-4754-8425-65E3A534C833 Q39645683-F4E57205-3799-4098-B90E-8299C60A5E1C Q40315198-80AAD29A-AF3E-4D66-9AC3-3CE33D20C963 Q40677793-CF4D7A30-539A-4276-920A-C7CD51FFD140 Q43096291-0A357C05-6586-4F7D-BA83-65BA1211B817 Q43751494-5DBFFBCC-C17B-4D97-ACC6-894AC3C667C1 Q44895959-D9C5989D-DAA9-4992-AEC3-5BBA7160E190 Q47661007-6B8FF22B-FF5C-4BF8-AA01-FE88583D3017 Q49168236-8D3F6934-0B03-49BD-8191-4B15CB7B867D

P2860

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

http://www.wikidata.org/entity/Q28202824

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@ast

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@en

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@nl

type

label

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@ast

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@en

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@nl

prefLabel

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@ast

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@en

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@nl

P1433

Q28202824-C0A7EA7B-8589-4398-AECE-DB8638B2A08B

P1476

Q28202824-BA855484-5A96-49E1-971E-E66B7CC6BFFF

P2093

Q28202824-051ADFD9-3855-4D46-8938-B33090FDAA9D

Q28202824-0E78E191-91B9-4A28-87D2-8DB157BD456C

Q28202824-1EEF45DC-7909-4C27-B88B-E9F47402915E

Q28202824-4062B951-EFB9-4396-8A35-CD6D69EC95C2

Q28202824-43B41CB5-E524-413B-83B3-02EF6FC532DD

Q28202824-4CCA2B12-1602-4725-9D9F-47F68E7D5E4F

Q28202824-67412E0C-255D-49B1-9A17-5F7AD5778771

Q28202824-67E6C6E9-F778-4429-B5BA-03BCD0965A14

Q28202824-7E9AFC67-F5FB-42DE-9E21-CB12820D05F7

Q28202824-854DD7E5-1769-4071-9825-EAAFD28F8D0B

P304

Q28202824-744EB0F9-5D35-4522-9BF0-F35C0BCDAE6C

P31

Q28202824-B52B87AD-B919-4870-B0A9-274509C37007

P3181

Q28202824-89FD1E8B-AB47-4D37-81C1-72A258B64EBC

P356

Q28202824-BD72368B-E2DA-48A1-8147-7AF9FF7CCE2B

P407

Q28202824-58904E50-5F90-47C1-ADCC-7A4919D74DD0

P433

Q28202824-D6609258-C1CE-4615-88F4-5B15ABE9AE6B

P478

Q28202824-FEA94C0C-1098-43CF-8BFB-10C1F239EE72

P577

Q28202824-891E08B2-99BE-4615-A8F9-78DB7C8932E5

P698

Q28202824-7EFF9F6B-08D9-42D7-BBAB-44309805ACD2

P921

Q28202824-28CB1D47-8335-4770-9B2E-C6C2439E0987

P3181

P356

JCO.2003.05.137

P1433

Journal of Clinical Oncology

P1476

Cantuzumab mertansine, a mayta ...... and biologic correlative study

@en

P2093

Amita Patnaik

http://www.w3.org/2001/XMLSchema#string

Anthony W Tolcher

http://www.w3.org/2001/XMLSchema#string

Charlene Audette

http://www.w3.org/2001/XMLSchema#string

Chris Takimoto

http://www.w3.org/2001/XMLSchema#string

Eric K Rowinsky

http://www.w3.org/2001/XMLSchema#string

Garry Schwartz

http://www.w3.org/2001/XMLSchema#string

Helen Martino

http://www.w3.org/2001/XMLSchema#string

Johann de Bono

http://www.w3.org/2001/XMLSchema#string

John M Lambert

http://www.w3.org/2001/XMLSchema#string

Kate Maes

http://www.w3.org/2001/XMLSchema#string

P304

211-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2479250

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2003.05.137

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12525512

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics